Asymchem Shares Surge Nearly 6% Afternoon Following Launch of 2 Billion Yuan Macromolecule Drug CDMO Project in Tianjin

Stock News04-24 14:28

Asymchem (06821) rose nearly 6% in afternoon trading. At the time of writing, the stock was up 5.49%, trading at HK$97.1, with a turnover of HK$44.5826 million.

The increase follows news that Asymchem has signed a memorandum of cooperation with the Tianjin Economic-Technological Development Area Administrative Committee. The agreement involves the continued expansion of a CDMO R&D and production base for innovative chemical macromolecule drugs within the Tianjin zone. The project is expected to involve a total investment of 2 billion yuan.

This initiative is projected to significantly enhance the company's integrated CDMO service capabilities for new molecular types such as peptides and oligonucleotides (TIDES), better meeting the diverse needs of its global partners.

Public data shows that in 2025, Asymchem's chemical macromolecule CDMO segment achieved operating revenue of 1.028 billion yuan, representing a year-on-year increase of 123.72%, making it the company's fastest-growing business unit.

The company anticipates it will have 4 peptide PPQ projects by 2026 and that its peptide solid-phase synthesis capacity will increase from 45,000 liters at the end of 2025 to 69,000 liters by the end of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173537758?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173537758","market":"other","top_or_hot":-1,"title":"Asymchem Shares Surge Nearly 6% Afternoon Following Launch of 2 Billion Yuan Macromolecule Drug CDMO Project in Tianjin","media":"Stock News","content":"<p>Asymchem (06821) rose nearly 6% in afternoon trading. At the time of writing, the stock was up 5.49%, trading at HK$97.1, with a turnover of HK$44.5826 million.</p>\n<p>The increase follows news that Asymchem has signed a memorandum of cooperation with the Tianjin Economic-Technological Development Area Administrative Committee. The agreement involves the continued expansion of a CDMO R&D and production base for innovative chemical macromolecule drugs within the Tianjin zone. The project is expected to involve a total investment of 2 billion yuan.</p>\n<p>This initiative is projected to significantly enhance the company's integrated CDMO service capabilities for new molecular types such as peptides and oligonucleotides (TIDES), better meeting the diverse needs of its global partners.</p>\n<p>Public data shows that in 2025, Asymchem's chemical macromolecule CDMO segment achieved operating revenue of 1.028 billion yuan, representing a year-on-year increase of 123.72%, making it the company's fastest-growing business unit.</p>\n<p>The company anticipates it will have 4 peptide PPQ projects by 2026 and that its peptide solid-phase synthesis capacity will increase from 45,000 liters at the end of 2025 to 69,000 liters by the end of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Asymchem Shares Surge Nearly 6% Afternoon Following Launch of 2 Billion Yuan Macromolecule Drug CDMO Project in Tianjin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAsymchem Shares Surge Nearly 6% Afternoon Following Launch of 2 Billion Yuan Macromolecule Drug CDMO Project in Tianjin\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-24 14:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Asymchem (06821) rose nearly 6% in afternoon trading. At the time of writing, the stock was up 5.49%, trading at HK$97.1, with a turnover of HK$44.5826 million.</p>\n<p>The increase follows news that Asymchem has signed a memorandum of cooperation with the Tianjin Economic-Technological Development Area Administrative Committee. The agreement involves the continued expansion of a CDMO R&D and production base for innovative chemical macromolecule drugs within the Tianjin zone. The project is expected to involve a total investment of 2 billion yuan.</p>\n<p>This initiative is projected to significantly enhance the company's integrated CDMO service capabilities for new molecular types such as peptides and oligonucleotides (TIDES), better meeting the diverse needs of its global partners.</p>\n<p>Public data shows that in 2025, Asymchem's chemical macromolecule CDMO segment achieved operating revenue of 1.028 billion yuan, representing a year-on-year increase of 123.72%, making it the company's fastest-growing business unit.</p>\n<p>The company anticipates it will have 4 peptide PPQ projects by 2026 and that its peptide solid-phase synthesis capacity will increase from 45,000 liters at the end of 2025 to 69,000 liters by the end of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1173537758","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173537758","pubTimestamp":1777012101,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Asymchem (06821) rose nearly 6% in afternoon trading. At the time of writing, the stock was up 5.49%, trading at HK$97.1, with a turnover of HK$44.5826 million. The increase follows news that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK0132":"高送转概念","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard","BK4139":"生物科技","BK1574":"生物医药B类股","06978":"永泰生物-B","06821":"凯莱英","BK1191":"制药","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","002821":"凯莱英","BK0239":"医药制造","CDMO":"Avid Bioservices, Inc."},"translate_title":"20亿元大分子药物CDMO项目天津启动凯莱英股价午后大涨近6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"CDMO":1,"VXUS":1,"06978":1,"06821":1,"002821":1},"content_text":"Asymchem (06821) rose nearly 6% in afternoon trading. At the time of writing, the stock was up 5.49%, trading at HK$97.1, with a turnover of HK$44.5826 million.\nThe increase follows news that Asymchem has signed a memorandum of cooperation with the Tianjin Economic-Technological Development Area Administrative Committee. The agreement involves the continued expansion of a CDMO R&D and production base for innovative chemical macromolecule drugs within the Tianjin zone. The project is expected to involve a total investment of 2 billion yuan.\nThis initiative is projected to significantly enhance the company's integrated CDMO service capabilities for new molecular types such as peptides and oligonucleotides (TIDES), better meeting the diverse needs of its global partners.\nPublic data shows that in 2025, Asymchem's chemical macromolecule CDMO segment achieved operating revenue of 1.028 billion yuan, representing a year-on-year increase of 123.72%, making it the company's fastest-growing business unit.\nThe company anticipates it will have 4 peptide PPQ projects by 2026 and that its peptide solid-phase synthesis capacity will increase from 45,000 liters at the end of 2025 to 69,000 liters by the end of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173537758","isCrawlerRequest":true}